Ibrutinib, a once-a-day drug that is administered orally, inhibits the first-in-class Bruton’s tyrosine kinase (BTK) that sends crucial signals to B cells to mature and produce antibodies, said
Enrollment has been completed for the AmpionTM Phase I US based clinical trial for IV treatment of COVID-19 patients requiring supplemental oxygen. The final results from the 5-day
Gavreto, a once-daily and oral precision therapy, will help selectively target RET alterations such as fusions and mutations irrespective of the tissue of origin. Roche’s wholly-owned member Genentech
Through this collaboration, HiFiBiO will use its proprietary technology platforms to identify novel AML targets and anti-AML specific antibodies for Kite’s use in cell therapies. “Kite is committed
The FDA approval, which enables to expand the label of once-weekly Trulicity to include 3.0mg and 4.5mg doses, was based on data from the AWARD-11 phase 3 trial,
These neutralizing effects were found to be comparable to or better than those seen with antibody candidates derived from patients who had recovered from COVID-19. The data were
Both firms have worked together to develop a vaccine candidate, which applies the same recombinant protein-based technology as one of Sanofi’s seasonal influenza vaccines with GSK’s pandemic adjuvant
AML is one of the most common acute leukemias in adults. The approval is based on results from the pivotal Phase 3 QUAZAR® AML-001 study in which treatment
The company has secured clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application of brequinar to treat Covid-19. Brequinar is an
The study will be conducted by investigators at leading U.S. academic medical centers, including Johns Hopkins Hospital, Emory University, Loma Linda University Health and The University of Texas
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.